Smart Pharma Optimizer
Polish clinical decision-support platform for medication safety. Smart Pharma Optimizer maps drug-disease interactions, adds up adverse-reaction probabilities across as many as thirty products, checks whether tablets may be split or crushed, and relays official regulatory safety alerts.
What is Smart Pharma Optimizer?
Smart Pharma Optimizer is a web platform built by Pharmdiver sp. z o.o., a company based in Bialystok, Poland, for healthcare professionals who have to keep a long medication list safe. Its opening argument is that polypharmacotherapy is a network of dependencies rather than a series of pairwise drug-drug checks, and the product is organised around that idea. Version 2 was released on 14 May 2026.
Five blocks make up the offering. Drug-disease interactions assess the situations where a coexisting condition changes how a medicine behaves, or where a medicine worsens the condition; relationships are modelled many-to-many and medicines are tied to ICD-10 codes. Drug card aggregates the therapeutic parameters of a product in one view: the full anatomical therapeutic chemical classification, every permitted route of administration, the separation between pharmacy reimbursement, drug programmes and the chemotherapy catalogue, and duplicate therapy detected at both active-substance and ATC-class level. Adverse-reaction summation computes cumulative risk as a product of independent events across up to thirty products, structured with the MedDRA dictionary and browsable by System Organ Class and High Level Group Term, with modifiers for age, sex, dose and route. Safe administration covers the decomposition of solid oral forms, off-label scenarios documented with clinical experts, feeding-tube guidance and a solvents and diluents module for parenteral preparation; a four-flag system marks each option as permitted, forbidden, conditional or undocumented, and every flag carries a direct quotation from the current Summary of Product Characteristics. Alerting watches the Polish medicines agency and the Chief Pharmaceutical Inspector, sending an email within thirty minutes of a new notice and tracking products at risk of shortage.
The company describes the underlying approach as artificial intelligence applied to decomposition checking and adverse-reaction summation, with pharmacists supervising the extraction algorithms and the MedDRA coding by hand whenever the match score is uncertain. Access is through a browser; integration with hospital or practice software is possible through an API supplied under a separate agreement. The publisher is explicit that the output is not advice and must be verified independently.
What it does
- Model drug-disease interactions as many-to-many relationships, linked to ICD-10 codes
- Add up adverse-reaction probabilities as a product of independent events, for up to thirty products at once, over ninety percent of the Polish SmPC database
- Say whether a solid oral form may be split, crushed, dissolved or chewed, with the SmPC sentence that proves it
- Give the rules for administering a medicine through a feeding tube or another artificial access
- Extract solvent and diluent guidance automatically for parenteral preparation
- Monitor URPL safety notices and Chief Pharmaceutical Inspector decisions in real time, mapped to trade names
- Open up drug-programme codes such as B.33, B.75 and B.98 with live links to the current criteria
When to use Smart Pharma Optimizer / When not to
A quick filter to help you decide if Smart Pharma Optimizer is the right fit.
When to use Smart Pharma Optimizer
- Hospital and clinical pharmacists reviewing complex medication lists ward by ward
- Prescribing physicians of any specialty, and above all those treating elderly or multimorbid patients
- Nurses and midwives who prepare and administer medicines, including by feeding tube
- Hospital quality and accreditation teams working towards the Polish FA1, FA2, FA5 and FA7 standards
- Lecturers and senior students of pharmacy, medicine and nursing faculties
When not to use Smart Pharma Optimizer
- Patients and the general public: an entry screen restricts the service to pharmacists and to people entitled to prescribe or trade in medicinal products
- Healthcare professionals outside Poland: the drug database, safety notices, reimbursement lists and drug-programme codes are entirely Polish
- Anyone looking for a free or self-service tool: access is granted on order, after a professional-licence check
- Teams expecting the software to make the clinical call: the terms state that the automated output is not advice of any kind
- Users who need a native mobile application: no iOS or Android app is published
How to use Smart Pharma Optimizer
A typical end-to-end flow, from setup to results.
- Pass the entry screen reserved for pharmacists and prescribers
- Open an account and pick your category: physician, pharmacist, medical graduate, student of pharmacy, medicine or dietetics, nurse, or university lecturer
- Enter your Polish professional practice number so the account can be verified
- For an institution, use the contact page or the online booking form to request a quote and place an order
- Sign in through the account page; an active subscription is required to reach the tool itself
- Work in a browser on Windows or macOS, ideally Chrome, with at least 4 GB of RAM and a stable connection
- Enter the patient's medicines and read the cumulative adverse-reaction view by organ system
- Check the four-flag panel before splitting, crushing or dissolving a solid oral form
- Follow the video guides for the decomposition, summation and ATC flow modules
- Optionally ask for API integration with the hospital or practice software, under a separate agreement
Pros & Cons
Pros
- Every clinical statement is traced to a named official source, from the Polish medicinal products register to the EMA, MedDRA and the URPL
- Each decomposition flag carries a verbatim quotation from the current Summary of Product Characteristics and a link to the document
- Content is refreshed continuously; safety notices reach the system within twenty-four hours and trigger an email within thirty minutes
- Pharmacists supervise the extraction algorithms and take over the MedDRA coding whenever the match score is uncertain
- A single check across thirty products is claimed to take sixty seconds
- Explicitly mapped to the Polish hospital accreditation standards FA1, FA2, FA5 and FA7 and to the primary-care standards
- Named, checkable references from the Medical University of Lodz, the Medical University of Silesia and a hospital medical director
Cons
- No public price at all: the only published offer is a quote scaled to the size of the institution
- Neither a free trial nor a permanent free plan is advertised
- Interface and content are Polish only, with no English version
- The regulatory scope is strictly Polish, which limits the tool outside that market
- Access requires a verified professional licence number, so the product cannot be evaluated unaided
- The site promises full functionality on mobile devices while clause 8.3 of the terms warns that mobile access may be less than optimal
- The publisher disclaims responsibility for the accuracy and completeness of the data and puts the burden of independent verification on the user
Pricing & Plans
No price is published. The offer page carries a single line of commercial information: hospital and ward deployments are quoted individually, priced according to the size of the institution, behind a request a quote button. The six shop pages listed in the sitemap all redirect to that offer page, and the basket and checkout pages redirect to each other, so no catalogue price is reachable. The terms confirm the arrangement: the amount due follows either the price shown in the service or the price set in the order, invoiced by VAT invoice and paid by bank transfer, with PayU named as the authorised payment provider. Neither a permanent free plan nor a free trial is advertised anywhere on the current site.
- physicians
- pharmacists
- nurses and midwives
- students from the fourth year onwards
- and academic lecturers
- Company account
- for legal entities
- pharmacies
- pharmaceutical wholesalers and healthcare providers
- opened on the basis of a signed order
- Hospital and ward deployment
- quoted individually according to the size of the institution
Data, GDPR & hosting
A consolidated view of how Smart Pharma Optimizer handles your data.
GDPR overview
Implementation is documented rather than merely claimed. The controller is named in full: Pharmdiver sp. z o.o., ul. Zurawia 71, 15-540 Bialystok, KRS 0000879722, NIP 9662146569, REGON 387984462. A data protection officer is designated and reachable by email. The privacy policy cites the GDPR (EU) 2016/679, the Polish Personal Data Protection Act of 10 May 2018, the Act of 18 July 2002 on electronic services and the Telecommunications Act, and it sets out a legal basis for each purpose under Article 6(1)(a), (b), (c) and (f). Seven data-subject rights are listed, including portability and the right to complain to the President of the UODO. The policy states that no automated decision-making with legal effect and no profiling take place, and that user data are not transferred outside the European Economic Area.
Who owns the data?
The publisher keeps everything. Clause 9.1 of the terms states that the service is the exclusive property of Pharmdiver, protected both by copyright and by the Polish Act of 27 July 2001 on the protection of databases; clause 8.9 extends that protection to the way the data are laid out on screen. Clause 9.2 forbids processing the content in order to make it available to third parties, online or offline, and clause 9.6 forbids unauthorised extraction and re-use of any part of the database, substantial or not. For personal data the position is different: the privacy policy names Pharmdiver as the controller, not a processor. The clinical content itself comes from public sources named in the terms, including the Polish medicinal products register, the EMA, MedDRA and the URPL.
Reuse rights
No, not freely. Anything published from the service must cite the service precisely, and clauses 9.4 and 9.5 require the publisher's prior written consent for any commercial publication. Clause 9.3 bars users from reusing, modifying or republishing a modified version of the publisher's work, and clause 9.6 bars building tools that would extract or re-use the database. Sharing account credentials with unauthorised people is separately forbidden by clause 5.8. Clause 9.7 sets out the consequences: the infringer returns or destroys every copy, makes good the damage and hands over any profit made. In practice a user may act on what the platform shows, but may not redistribute it.
Data retention & training
Hosting summary
The site never says where the data are physically hosted. No country, no region and no hosting provider is named on any of the pages collected. What is published is a transfer commitment rather than a hosting declaration: the privacy policy states that users' personal data will not be transferred outside the European Economic Area, and the data protection section of the terms repeats the point while allowing an exception where a transfer is necessary to deliver the service, subject to appropriate GDPR safeguards. On recipients the disclosure is partial: PayU is named as the authorised payment provider, with a link to its own privacy information, and the remaining recipients are given only as categories, namely accounting, law firms and IT and hosting suppliers. The controlling jurisdiction is unambiguous, since the controller is a Polish company registered in Bialystok, but the storage location itself has to be treated as undisclosed.
Things to keep in mind
Risks and trade-offs to weigh before adopting Smart Pharma Optimizer.
- The output is explicitly not advice: clause 5.1 of the terms states that the features rest on an automated process that constitutes no form of advice, legal or otherwise
- The publisher disclaims responsibility for the completeness, accuracy, currency and availability of data drawn from external sources, and clause 11.3 requires users to verify anything that will drive a decision with legal, health, financial or business consequences
- The computed cumulative risk is described by the publisher itself as underestimated: dose, duration, combined treatment and demographics still have to be weighed by the clinician
- Update latency is documented and non-zero: a new medicine may appear up to seven days late once fully decomposed, and a safety notice takes up to seven days to be attached to the right adverse reaction
- Over-reliance is the real hazard in daily use: a fast, confident answer on screen can quietly replace the pharmacological reasoning it is meant to support
- The site and the terms contradict each other on mobile use, so a ward workflow built on phones may not behave as the commercial pages promise
- Two different data protection officer addresses are published, one of them on a domain belonging to the publisher's earlier project brand, which makes a data-subject request easy to send to the wrong place
Setup & Integrations
Technical difficulty
Low for the end user. There is nothing to deploy: you register, have your professional licence number verified, and work in a browser. The terms ask for a current operating system, a current browser with Chrome recommended, an active email account, Windows or macOS, around 4 GB of RAM and a stable connection, and note that a desktop, laptop or tablet gives better results than a phone. Difficulty rises only if you want the API integration with hospital or practice software, which is a separate agreement on the publisher's technical and licensing terms, with full compatibility not guaranteed.
Deployment
Supported languages
Behind Smart Pharma Optimizer
Social
Resources
All the official URLs gathered for verification and reference.
Frequently asked questions
What does Smart Pharma Optimizer actually do?
Who is allowed to open an account?
How much does it cost?
Is there a free trial or a free plan?
How are adverse reactions added up?
What does the flag system mean?
How often are the data updated?
Can it be plugged into a hospital or practice system?
Is there a mobile application?
In which languages is it available?
Should you pick Smart Pharma Optimizer?
Smart Pharma Optimizer is a narrow, serious product. It does one thing, medication safety in a polypharmacy setting, and it does it with an unusual degree of traceability: every decomposition flag carries the sentence from the Summary of Product Characteristics that justifies it, the adverse-reaction data are coded against MedDRA under pharmacist supervision, and the regulatory sources are named one by one in the terms. The alignment with the Polish hospital accreditation standards, the named academic references and the continuous update cycle all point to a team that understands the environment it sells into.
Two things will decide whether it is relevant to a given reader. The first is geography: the drug database, the safety notices, the reimbursement lists and the drug-programme codes are Polish, the interface is Polish, and nothing suggests an international edition is planned. Outside Poland the tool has little to offer. The second is commercial opacity. There is no published price, no free plan and no trial; the shop pages that once existed now redirect to a quote request, and access requires a verified professional licence number. A hospital pharmacy department can work with that; an individual practitioner who wants to try before committing cannot.
The publisher is transparent about the limits of the tool, perhaps more than most: the terms say in so many words that the automated output is not advice, that the data may be incomplete, and that the user must verify independently before acting. That is the correct posture for clinical software, and it should be read as a condition of use rather than as small print. Version 2, released in May 2026, suggests the roadmap is active.
- Choosing a selection results in a full page refresh.
- Opens in a new window.